Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

Ugur H. C., Ramakrishna N., Bello L., Menon L. G., Kim S., Black P. M., ...More

JOURNAL OF NEURO-ONCOLOGY, vol.83, no.3, pp.267-275, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 83 Issue: 3
  • Publication Date: 2007
  • Doi Number: 10.1007/s11060-007-9337-z
  • Journal Name: JOURNAL OF NEURO-ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.267-275
  • Keywords: histone deacetylase inhibitor, glioma, local delivery, SAHA, HISTONE DEACETYLASE INHIBITOR, CANCER-CELL-GROWTH, IN-VIVO, MALIGNANT GLIOMAS, ANTINEOPLASTIC ACTIVITY, CARCINOMA CELLS, HDAC INHIBITOR, BRAIN-TUMORS, DNA-REPAIR, PHASE-I
  • Ankara University Affiliated: No

Abstract

Object Current treatments for malignant gliomas produce only a modest increase in survival time. New therapeutic approaches are desperately needed. Suberoylanilide hydroxamic acid (SAHA) is an effective inhibitor of the growth of many solid and hematological malignancies. Nevertheless, very few studies have investigated the effects of SAHA on glial tumors. The present study was designed to investigate the therapeutic effects of the intracranial local delivery of SAHA in an orthotopic glioma model.